Refine by
Breast Cancer Treatment Articles & Analysis
42 news found
The portfolio features both a tumor-naïve assay and a tumor-informed assay that are designed to help detect residual disease or early cancer recurrence and monitor for immunotherapy treatment response, providing valuable insights to inform patient management strategies. ...
ByTempus
Food and Drug Administration (FDA) has approved ORSERDU for the treatment of postmenopausal women or adult men, with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. ...
CEM is an emerging modality that combines digital mammography with the administration of a contrast agent, such as Ultravist, to support the diagnosis of breast cancer and guide treatment decisions. The approval expands Bayer’s radiology portfolio, which includes contrast media, injectors as well as digital and artificial intelligence (AI) ...
ByBayer AG
“We are excited to initiate this collaboration with Menarini to explore the potential of samuraciclib in combination with elacestrant for the treatment of advanced breast cancer,” said Tim Pearson, Chief Executive Officer of Carrick Therapeutics. ...
(“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, announced preliminary Phase 2 data from the ongoing SMILE trial of onapristone extended release (ONA-XR), the company’s novel, first-in-class, potent, orally administered ...
Elacestrant demonstrated longer progression-free survival (PFS) vs SOC endocrine therapy with medians up to 8.6 months, positively associated with the duration of prior treatment with CDK4/6 inhibitors Elacestrant side effects were manageable and consistent with previously reported results Results demonstrate that elacestrant may have the potential to become a new standard of ...
Study plans to investigate elinzanetant as non-hormonal treatment for vasomotor symptoms caused by endocrine therapy in breast cancer patients Elinzanetant is an innovative non-hormonal development compound in development for the treatment of vasomotor symptoms during menopause Bayer, a global leader in women’s ...
ByBayer AG
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces today that it has added Mayo Clinic, Jacksonville, Florida as a clinical site in the Phase I/II study of BriaCell’s lead candidate, Bria-IMT, with Incyte’s PD-1 ...
October marks a month dedicated to a cause close to the core of everything which we do at Cirdan: Breast Cancer Awareness. This month will see a surge in activism surrounding breast cancer awareness and a push for finding a cure from around the globe. The fight to treat and cure breast cancer continues constantly, and we pride ourselves in taking part in the fight to save lives. Breast cancer ...
The USA boasts better cancer survival rates than most other developed countries. This was made possible due to a number of factors. In America, much attention is paid to medical equipment. Local oncology centers are equipped with the latest technology, actively use innovative technologies and new medicines. In addition, oncology in the United States involves extensive screening and more ...
This clinical investigation called TIDE, had a first successful implantation by 12th of July at the Institute of Clinical Oncology with a 63 years old patient operated with MATTISSE in the case of her breast cancer and immediate reconstruction. CE marking, industrialisation and hiring for the marketing of MATTISSE The second objective of this fundraising is to ...
Patients with incurable breast cancer could potentially benefit from new Welsh-led research, latest evidence suggests. ...
Patients with DCIS have cancerous cells lining the milk ducts of the breast, but they have not spread into surrounding breast tissue. ...
The ICE3 trial was designed to evaluate the safety and efficacy of breast cryoablation with IceCure’s ProSense® System, enabling women older than 60 with low-risk early-stage breast cancers to benefit from a non-surgical treatment and avoid the associated surgical risks. ...
Regor Therapeutics Group, a clinical-stage biotech company focusing on immunology, oncology, and metabolic disorders, announced today that the first patient has been dosed in the Phase I clinical trial of the Company’s next generation targeted inhibitor RGT-419B for the treatment of breast cancer. RGT-419B is a new generation CDK2/4/6, ...
(“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that five abstracts have been selected for poster or symposium presentations at the American Association for Cancer ...
Updated RxPONDER study analysis provides further evidence that the test identifies the majority of women with early-stage, node-positive breast cancer who can avoid chemotherapy Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the presentation of new data at the 2021 San Antonio ...
RxPONDER, an independent study led by SWOG Cancer Research Network, demonstrates that guiding treatment with Oncotype DX test can spare chemotherapy use in majority of postmenopausal women Results have already led to updated NCCN Guidelines® for breast cancer New RxPONDER results to be featured in oral presentation at ...
Dense breasts increase cancer risk by 4-6 times5, affecting more than 40 percent of women3. ...
Study Demonstrate Superiority of VeraForm® Marker Over Clips For Tumor Bed Delineation Accuracy San Francisco CA, October 28, 2021- Videra Surgical Inc., the developer of the novel adaptable tumor bed marker VeraForm® for breast cancer surgery, announced the presentation of an independent study at this week’s ASTRO conference in Chicago ...